These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 22482055)

  • 1. Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies.
    Montaigne D; Hurt C; Neviere R
    Biochem Res Int; 2012; 2012():951539. PubMed ID: 22482055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and cellular mechanisms of anthracycline cardiotoxicity.
    Chen B; Peng X; Pentassuglia L; Lim CC; Sawyer DB
    Cardiovasc Toxicol; 2007; 7(2):114-21. PubMed ID: 17652815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
    Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
    Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracyclines and mitochondria.
    Mordente A; Meucci E; Silvestrini A; Martorana GE; Giardina B
    Adv Exp Med Biol; 2012; 942():385-419. PubMed ID: 22399433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.
    Rochette L; Guenancia C; Gudjoncik A; Hachet O; Zeller M; Cottin Y; Vergely C
    Trends Pharmacol Sci; 2015 Jun; 36(6):326-48. PubMed ID: 25895646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
    Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
    Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of mitochondria in doxorubicin-mediated cardiotoxicity: from molecular mechanisms to therapeutic strategies.
    Wang T; Xing G; Fu T; Ma Y; Wang Q; Zhang S; Chang X; Tong Y
    Int J Med Sci; 2024; 21(5):809-816. PubMed ID: 38617011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing and Treating Anthracycline Cardiotoxicity: New Insights.
    Sawicki KT; Sala V; Prever L; Hirsch E; Ardehali H; Ghigo A
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():309-332. PubMed ID: 33022184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
    Agunbiade TA; Zaghlol RY; Barac A
    Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
    Conklin KA
    Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Cardiomyopathy in Breast Cancer: How Can We Attenuate the Risk of Heart Failure from Anthracyclines and Anti-HER2 Therapies?
    Kimmick G; Dent S; Klem I
    Curr Treat Options Cardiovasc Med; 2019 May; 21(6):30. PubMed ID: 31152324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
    Schneider JW; Chang AY; Rocco TP
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
    Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
    J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions.
    Osataphan N; Phrommintikul A; Chattipakorn SC; Chattipakorn N
    J Cell Mol Med; 2020 Jun; 24(12):6534-6557. PubMed ID: 32336039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of anthracycline cardiotoxicity in children and adults.
    Grenier MA; Lipshultz SE
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines.
    Vasti C; Hertig CM
    World J Cardiol; 2014 Jul; 6(7):653-62. PubMed ID: 25068025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.